Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of JTT-252 in Healthy and Type 2 Diabetic Subjects
NCT02120976Phase 1Terminated
- Sponsor
- Akros Pharma Inc.
- Start
- Apr 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of JTT-252 in type 2 diabetes mellitus (T2DM) (9 arms), sponsored by Akros Pharma Inc. Primary endpoints: Number of subjects with adverse events at 22 days, Vital signs and 12 lead ECGs at 22 days and 5 more. Started Apr 2014; status: terminated.
02
Drugs
JTT-252
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02120976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120976.